Visiopharm® is a world leader in Augmented Pathology™ solutions; that comprise precision pathology and high-throughput pathology for tissue-diagnostics and research.

Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and diagnostic pathology labs all over the world utilize the Oncotopix® platform for tissue-based research and diagnostics. The newest advancements in artificial intelligence and deep learning further consolidates Oncotopix® as the most comprehensive and highly configurable solution for tissue analysis on the market today.

Our solutions are featured in over 1300 peer-reviewed scientific publications compatible with leading slide scanner manufacturers and data management software. Visiopharm® is certified according to EN ISO 13485:2016, covering design, development, manufacture, installation, and service of in vitro diagnostics pathology software.

Visiopharm, a privately-owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis.

Our company has grown into an international business with over 900 licenses in more than 38 countries. Our growing network of authorized distributors and partners support the growth of Visiopharm’s solutions on several continents including North America, Europe, and Asia.

Our headquarters is in the Medicon Valley of Denmark, with a branch office in the United Kingdom, and a North American office in Colorado.